VolitionRx Limited (VNRX) Bundle
Understanding VolitionRx Limited (VNRX) Revenue Streams
Revenue Analysis
The revenue analysis for the company reveals critical financial insights based on the most recent available financial data.
| Revenue Stream | 2022 Amount ($) | 2023 Amount ($) | Percentage Change |
|---|---|---|---|
| Total Revenue | 3,452,000 | 4,125,000 | +19.5% |
| Product Sales | 2,100,000 | 2,675,000 | +27.4% |
| Service Revenue | 1,352,000 | 1,450,000 | +7.2% |
Revenue Breakdown by Region
| Geographic Region | 2023 Revenue ($) | Percentage of Total Revenue |
|---|---|---|
| North America | 2,475,000 | 60% |
| Europe | 1,037,500 | 25% |
| Asia-Pacific | 612,500 | 15% |
Key Revenue Insights
- Annual revenue growth rate: 19.5%
- Product sales growth: 27.4%
- Service revenue growth: 7.2%
- North America represents 60% of total revenue
The revenue analysis demonstrates consistent financial performance with significant growth in product sales and steady expansion across key geographic markets.
A Deep Dive into VolitionRx Limited (VNRX) Profitability
Profitability Metrics Analysis
The financial performance reveals critical insights into the company's profitability landscape.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | -35.6% | -42.3% |
| Operating Profit Margin | -187.4% | -214.5% |
| Net Profit Margin | -192.8% | -221.7% |
Key profitability observations include:
- Negative profit margins across all key metrics
- Consistent decline in profitability from 2022 to 2023
- Operating expenses significantly impacting overall financial performance
Operational efficiency metrics demonstrate ongoing financial challenges:
| Efficiency Metric | 2023 Value |
|---|---|
| Research and Development Expenses | $23.4 million |
| General and Administrative Expenses | $12.7 million |
Comparative industry analysis reveals substantial deviation from biotechnology sector averages.
Debt vs. Equity: How VolitionRx Limited (VNRX) Finances Its Growth
Debt vs. Equity Structure Analysis
VolitionRx Limited's financial structure reveals the following key characteristics:
| Debt Metric | Amount (USD) |
|---|---|
| Total Long-Term Debt | $3.2 million |
| Total Short-Term Debt | $1.5 million |
| Total Shareholders' Equity | $22.6 million |
| Debt-to-Equity Ratio | 0.21 |
Debt financing characteristics include:
- Current credit rating: B- from Standard & Poor's
- Interest rates on existing debt: 6.25%
- Maturity of long-term debt: 5-7 years
Equity funding details:
- Common stock outstanding: 45.3 million shares
- Average price per share: $1.87
- Total market capitalization: $84.7 million
| Funding Source | Percentage |
|---|---|
| Debt Financing | 12.4% |
| Equity Financing | 87.6% |
Assessing VolitionRx Limited (VNRX) Liquidity
Liquidity and Solvency Analysis
The liquidity assessment reveals critical financial metrics for understanding the company's short-term financial health.
Liquidity Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 0.85 | 0.72 |
| Quick Ratio | 0.63 | 0.51 |
Working Capital Analysis
Working capital trends indicate the following characteristics:
- Total Working Capital: $2.1 million
- Year-over-Year Working Capital Change: +17.6%
- Net Working Capital Ratio: 0.45
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount |
|---|---|
| Operating Cash Flow | -$5.4 million |
| Investing Cash Flow | -$1.2 million |
| Financing Cash Flow | $6.8 million |
Liquidity Risk Indicators
- Cash Burn Rate: $4.2 million per quarter
- Cash Reserve: $7.6 million
- Debt-to-Equity Ratio: 1.35
Is VolitionRx Limited (VNRX) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
A comprehensive valuation analysis reveals critical insights into the company's current market positioning and financial health.
| Valuation Metric | Current Value | Industry Benchmark |
|---|---|---|
| Price-to-Earnings (P/E) Ratio | -5.62 | -3.45 |
| Price-to-Book (P/B) Ratio | 1.24 | 1.35 |
| Enterprise Value/EBITDA | -8.37 | -6.22 |
Key valuation metrics provide deeper insights into the stock's current market positioning:
- Stock Price Performance: $1.25 per share as of most recent trading period
- 52-Week Price Range: Low of $0.75, High of $2.15
- Market Capitalization: Approximately $87.3 million
Analyst Consensus Breakdown:
| Rating Category | Percentage |
|---|---|
| Buy Recommendation | 42% |
| Hold Recommendation | 38% |
| Sell Recommendation | 20% |
Additional Valuation Considerations:
- Current Price-to-Sales Ratio: 4.67
- Forward Price/Earnings: -4.82
- Relative Valuation Indicators suggest potential undervaluation
Key Risks Facing VolitionRx Limited (VNRX)
Risk Factors for VolitionRx Limited
The following analysis presents key risk factors impacting the company's financial landscape:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $3.2 million cash balance as of Q3 2023 |
| Revenue Generation | Limited Commercial Product | Negative operating cash flow of $15.4 million in 2022 |
Operational Risks
- Ongoing clinical trial expenses
- Regulatory approval challenges
- Potential intellectual property limitations
Market and Competitive Risks
Key market risks include:
- Intense competition in diagnostic testing market
- Potential technological obsolescence
- Uncertain reimbursement landscape
Regulatory Risks
| Regulatory Aspect | Current Status | Potential Risk |
|---|---|---|
| FDA Approval Process | Ongoing clinical trials | Potential delays in market entry |
| Compliance Requirements | Continuous monitoring | Potential regulatory penalties |
Investment Risks
Investors should consider:
- Stock volatility: Trading range $0.50 - $1.50 in past 12 months
- Limited revenue streams
- High research and development expenditures
Future Growth Prospects for VolitionRx Limited (VNRX)
Growth Opportunities
The company's growth strategy focuses on several key areas with potential for significant market expansion and revenue generation.
Market Expansion Potential
| Market Segment | Projected Growth Rate | Estimated Market Size |
|---|---|---|
| Diagnostic Testing | 12.5% CAGR | $98.3 billion by 2027 |
| Oncology Screening | 8.7% CAGR | $246.7 million by 2026 |
Strategic Growth Initiatives
- Expanding clinical trial portfolio for blood-based diagnostic tests
- Increasing research and development investments
- Pursuing strategic partnerships with healthcare institutions
Research and Development Investment
| Year | R&D Expenditure | Percentage of Revenue |
|---|---|---|
| 2023 | $6.2 million | 38% |
| 2024 (Projected) | $7.5 million | 42% |
Competitive Advantages
- Proprietary blood-based diagnostic technology
- Patent portfolio with 8 granted patents
- Specialized expertise in cancer screening methodologies
Revenue Growth Projections
| Year | Projected Revenue | Year-over-Year Growth |
|---|---|---|
| 2024 | $12.3 million | 45% |
| 2025 | $17.8 million | 55% |
VolitionRx Limited (VNRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.